Work

A randomized double-blind, placebo-controlled study of omalizumab for idiopathic anaphylaxis

Year: 2020

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Journal of Allergy and Clinical Immunology

DOI: 10.1016/j.jaci.2020.11.005

Authors: Melody C. Carter, Irina Maric, Erica H. Brittain, Yun Bai, Keith Lumbard, Hyejeong Bolan, Daly Cantave, Linda M. Scott, Dean D. Metcalfe

Institutions: National Institutes of Health, National Institute of Allergy and Infectious Diseases, National Institutes of Health Clinical Center, Frederick National Laboratory for Cancer Research

Language: English

Topic: Mast cells and histamine

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Cancer Institute

Award: G4689185066

OpenAlex ID: W3098785557

FWCI: 2.273

Cites: 60

Cited by: 38

Related to: 10